University of Manitoba, Winnipeg, Manitoba, Canada.
Memorial Sloan-Kettering Cancer Center, New York, NY.
J Thorac Cardiovasc Surg. 2023 Sep;166(3):637-654. doi: 10.1016/j.jtcvs.2023.04.039. Epub 2023 Jun 10.
Novel targeted therapy and immunotherapy drugs have recently been approved for use in patients with surgically resectable lung cancer. Accurate staging, early molecular testing, and knowledge of recent trials are critical to optimize oncologic outcomes in these patients.
最近,一些新型靶向治疗和免疫治疗药物已获准用于可手术切除的肺癌患者。准确的分期、早期分子检测以及对最新临床试验的了解,对于优化这些患者的肿瘤学结局至关重要。